<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04147962</url>
  </required_header>
  <id_info>
    <org_study_id>IRBN672019</org_study_id>
    <nct_id>NCT04147962</nct_id>
  </id_info>
  <brief_title>Intense Pulsed Light in Meibomian Gland Dysfunctions</brief_title>
  <acronym>LACRYSTIM</acronym>
  <official_title>Intense Pulsed Light in Meibomian Gland Dysfunctions: Retrospective Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Saint Etienne</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Quantel Medical</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Saint Etienne</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Dry eye disease (DED) is an extremely common disease whose meibomian gland dysfunction is the
      main etiology.

      Polychromatic intense pulsed light (IPL) is a promising new therapeutic alternative but few
      clinical data have been published.

      A new IPL device has recently been marketed: LACRYSTIM (QUANTEL, France). The investigators
      have been using it in our clinical practice since June 2019.

      The investigators present a retrospective study on our first clinical results.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 25, 2019</start_date>
  <completion_date type="Anticipated">October 2020</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Lacrydiag in current clinical practice</measure>
    <time_frame>6 months</time_frame>
    <description>The LacryDiag ocular surface analyzer is used for the diagnosis of dry eyes.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>collection of adverse events</measure>
    <time_frame>6 months</time_frame>
    <description>-data concerning the safety: presence or absence of adverse events during treatment or afterwards (burns, tingling, redness of skin ...)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ocular Surface Disease Index questionnaire</measure>
    <time_frame>6 months</time_frame>
    <description>measured in current clinical practice. This 12-item questionnaire assesses dry eye symptoms and the effects it has on vision-related function in the past week of the patient's life. The questionnaire has 3 subscales: ocular symptoms, vision-related function, and environmental triggers.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Slit lamp Photography x16 and x25</measure>
    <time_frame>6 months</time_frame>
    <description>in current clinical practice</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Oxford Score</measure>
    <time_frame>6 months</time_frame>
    <description>measured in current clinical practice. The Oxford score is used to assess epithelial damage to the cornea and conjunctiva.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Break-up time Test</measure>
    <time_frame>6 months</time_frame>
    <description>measured in current clinical practice. The measurement of the tear film rupture time determines the stability of the tear film, i.e. the degree of humidification of the eyes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Schirmer Test</measure>
    <time_frame>6 months</time_frame>
    <description>measured in current clinical practice. Determination of the quantity of tears produced.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Dry Eye Syndromes</condition>
  <condition>Meibomian Gland Dysfunction</condition>
  <arm_group>
    <arm_group_label>Patients with dry eye disease with meibomian gland dysfunction</arm_group_label>
    <description>Collected data from patient records for consultations Day 0, Day 15 and Day 45 (3 treatment sessions) and Months 3, Months 6 (follow-up consultations).
- parameters used for each treatment session: duration of treatment session and intensity of intense pulsed light</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>intense pulsed light (usual practice)</intervention_name>
    <description>collection data : parameters used for each treatment session: duration of treatment session and intensity of intense pulsed light</description>
    <arm_group_label>Patients with dry eye disease with meibomian gland dysfunction</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with Dry eye disease with meibomian gland dysfunction, preferentially mild to
        moderate, and having benefited from intense pulsed light treatment
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with Dry eye disease with meibomian gland dysfunction, preferentially mild to
             moderate, and having benefited from intense pulsed light treatment.

          -  patient affiliated with a social security organization

        Exclusion Criteria:

          -  patient with incomplete follow-up
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marie Caroline TRONE, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHU de Saint Etienne</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marie Caroline TRONE, MD</last_name>
    <phone>0477829428</phone>
    <phone_ext>+33</phone_ext>
    <email>m.caroline.trone@chu-st-etienne.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU de Saint Etienne</name>
      <address>
        <city>Saint Etienne</city>
        <zip>42055</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marie Caroline TRONE, MD</last_name>
      <phone>(0)4 77 12 70 12</phone>
      <phone_ext>+33</phone_ext>
      <email>m.caroline.trone@chu-st-etienne.fr</email>
    </contact>
    <investigator>
      <last_name>Marie Caroline TRONE, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Philippe GAIN, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gilles THURET, MD PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 25, 2019</study_first_submitted>
  <study_first_submitted_qc>October 31, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 1, 2019</study_first_posted>
  <last_update_submitted>October 31, 2019</last_update_submitted>
  <last_update_submitted_qc>October 31, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>intense pulsed light</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dry Eye Syndromes</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

